Clinical trial
Oct 2026
Efficacy and safety of switching to once-daily oral doravirine plus raltegravir in virologically suppressed people with HIV-1: a randomized, open-label, multicentre phase 2 study (DORAL).
R. Palich, M. Lê, A. Castagna et al.
· Journal of Antimicrobial Che... · 0 citations